Shingles Rates Are Going Up (And What You Can Do About It)

shingles rates

The number of individuals who end up developing shingles is increasing.

An article published on April 14, 2014 on Medscape.com said that all across America, Herpes Zoster rates “have increased by 39% from 1992 to 2010 among adults older than 65 years of age.” (1) This data comes from a recent CDC study, using Medicare data from 1992 to 2010.

Some scientists believe that the increase in herpes zoster is associated with the widespread vaccination of children against the varicella zoster virus, which also causes chickenpox.

However, a growing body of evidence shows that this is unlikely. Another theory says “that exposure to varicella disease may boost a person’s immunity to VZV and reduce the risk for VZV reactivation as zoster. Some studies have shown reduced risk for zoster in adults who are exposed to varicella, but other studies have not shown this effect.” (1)

Regardless of the reason for the increase, Dr. Hales, one of the authors of the article mentioned above, wrote that “we do know that many cases of zoster could be prevented by the zoster vaccine. CDC recommends that adults aged 60 years or older receive 1 dose of zoster vaccine to help prevent the disease and its potentially debilitating complications, including post-herpetic neuralgia (1).”

“Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus stays in the body in a dormant (inactive) (latent) state. For reasons that are not fully known, the virus can reactivate years later, causing shingles.” (2)

herpes zoster prevention

Are there treatments that target the Varicella Zoster Virus (VZV)?

Yes there is.

Zostavax is a vaccine that may reduce the risk of developing a shingles outbreak, and decrease the long-term pain from post-herpetic neuralgia (PHN). In adults vaccinated at age 60 years or older, however, protection from the vaccine decreases within the first 5 years after vaccination.

There are also antiviral drugs, such as Zovirax or Valtrex. However, these medications, when effective, only work to shorten the time of the shingles outbreak. They are ineffective against the latent VZV virus.

Gene-Eden-VIR and Novirin are natural remedies designed to help the immune system target latent herpes viruses, including the VZV. A recent clinical study tested the effect of the Novirin and Gene-Eden-VIR formula on viral infections, including an infection with herpes viruses.

VZV is a member of the herpes family of viruses.

Novirin shares the same formula as Gene-Eden-VIR. The difference between the two is that Novirin has higher quality, more expensive ingredients. The Novirin/Gene-Eden-VIR formula was tested in two post-marketing clinical studies published in September 2013 and March 2014, respectively, in the peer reviewed medical journal Pharmacy & Pharmacology. However, Novirin contains higher quality, more expensive ingredients. These ingredients were selected to fight latent viruses even more effectively than Gene-Eden-VIR.

“Because of the increase in the shingles rate, we recommend that people talk to their doctors about Novirin or Gene-Eden-VIR, the most effective natural antiviral products on the market.” – The TargetShingles.com Team

Interested individuals can view the two published studies on the Novirin and Gene-Eden-VIR formula here, http://cbcd.net/Gene-Eden-VIR-Clinical-Study.php and http://cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php.

References:

(1) Herpes Zoster Rates Are Increasing, but Why? Published on April 14, 2014.
http://www.medscape.com/viewarticle/822982

(2) CDC – Shingles (Herpes Zoster). Last Updated January 10, 2011.
http://www.cdc.gov/shingles/about/overview.html

(3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U056hVWSz90

(4) Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Published in March 2014.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.U056t1WSz90